Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis

Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis

<b>Background/Objectives:</b> Glecaprevir/pibrentasvir (G/P) and elbasvir/grazoprevir (EBR/GZR) are effective treatments for chronic hepatitis C (CHC), especially in patients with chronic kidney disease (CKD). However, both regimens carry a risk of drug-induced liver injury (DILI). This...

Full description

Saved in:
Bibliographic Details
Main Authors: Hsuan-Yu Hung, Wei-Liang Hung, Ye Gu, Chung-Yu Chen
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Biomedicines
Subjects:
drug-induced liver injury
DILI
liver damage
elbasvir/grazoprevir
glecaprevir/pibrentasvir
chronic kidney disease
Online Access:https://www.mdpi.com/2227-9059/13/1/55
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items